Recordati
Recordati is an Italian pharmaceutical group whose rare-disease arm markets oncology and haematology products in Europe, including siltuximab (Sylvant), chlormethine gel (Ledaga) and dinutuximab beta (Qarziba).
Overview
Recordati Rare Diseases acquired EUSA Pharma in 2022, adding Sylvant (siltuximab) for multicentric Castleman disease, Qarziba (dinutuximab beta) for high-risk neuroblastoma and Fotivda (tivozanib) in Europe, alongside Ledaga (chlormethine gel) licensed from Helsinn.
Scorecard
All companies- approved products +12
- targets +2
- modalities +4
- regions +2
- registry trials +30
Mechlorethamine, or nitrogen mustard, was the first chemotherapy ever used, in 1940s Hodgkin lymphoma. Today its main use is as a skin gel (Valchlor in the US, Ledaga in Europe) for early cutaneous T-cell lymphoma.
Siltuximab (Sylvant) is an antibody that neutralises the inflammatory messenger interleukin-6. It is the only approved treatment for multicentric Castleman disease, a rare lymph node disorder, in people without HIV or HHV-8 infection.